AstraZeneca Discontinues PPAR Candidate Galida, Readies New Crestor Claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca will discontinue development of its Phase III dual peroxisome proliferator-activator receptor agonist Galida due to safety concerns associated with the class, according to the company